Pfizer Inc. (PFE)

$25.4

+0.14

(+0.55%)▲

Market is closed - opens 7 PM, 29 Apr 2024
star icon

Pfizer Inc is a multinational pharmaceutical corporation that produces and develops a wide range of innovative health products.

Insights on Pfizer Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 12.73B → 14.24B (in $), with an average increase of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 5.54B → -3.34B (in $), with an average decrease of 100.2% per quarter

  • Vs PG

    In the last 1 year, Procter & Gamble Company, The has given 5.2% return, outperforming this stock by 39.8%

  • Vs PG

    In the last 3 years, Procter & Gamble Company, The has given 23.8% return, outperforming this stock by 58.5%

Performance

  • $25.29
    $25.54
    $25.40
    downward going graph

    0.45%

    Downside

    Day's Volatility :0.99%

    Upside

    0.55%

    downward going graph
  • $25.23
    $38.81
    $25.40
    downward going graph

    0.67%

    Downside

    52 Weeks Volatility :34.99%

    Upside

    34.55%

    downward going graph

Returns

PeriodPfizer Inc.Sector (Health Care)S&P500
3 Months
-8.05%
0.5%
3.2%
6 Months
-18.93%
11.7%
22.0%
1 Year
-34.61%
6.2%
24.5%
3 Years
-34.69%
13.5%
20.6%

Highlights

Market Capitalization
148.8B
Book Value
$15.77
Dividend Share
1.64
Dividend Yield
6.4%
Earnings Per Share (EPS)
0.37
PE Ratio
71.0
PEG Ratio
0.26
Wall Street Target Price
31.1
Profit Margin
3.62%
Operating Margin TTM
-49.97%
Return On Assets TTM
1.55%
Return On Equity TTM
2.35%
Revenue TTM
58.5B
Revenue Per Share TTM
10.37
Quarterly Revenue Growth YOY
-41.3%
Gross Profit TTM
66.2B
EBITDA
11.5B
Diluted Eps TTM
0.37
Quarterly Earnings Growth YOY
-0.76
EPS Estimate Current Year
2.21
EPS Estimate Next Year
2.73
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
0.53

Analyst Recommendation

Buy
    51%Buy
    48%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Pfizer Inc.(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
15
Hold
14
15
16
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22.44%

Current $25.40
Target $31.10

Company Financials

FY18Y/Y Change
Revenue
53.6B
↑ 2.1%
Net Income
11.2B
↓ 47.66%
Net Profit Margin
20.79%
↓ 19.76%
FY19Y/Y Change
Revenue
51.8B
↓ 3.54%
Net Income
16.3B
↑ 45.91%
Net Profit Margin
31.45%
↑ 10.66%
FY20Y/Y Change
Revenue
41.9B
↓ 19.02%
Net Income
7.0B
↓ 56.86%
Net Profit Margin
16.75%
↓ 14.7%
FY21Y/Y Change
Revenue
81.3B
↑ 93.97%
Net Income
22.0B
↑ 213.09%
Net Profit Margin
27.04%
↑ 10.29%
FY22Y/Y Change
Revenue
100.3B
↑ 23.43%
Net Income
31.4B
↑ 42.74%
Net Profit Margin
31.27%
↑ 4.23%
FY23Y/Y Change
Revenue
58.5B
↓ 41.7%
Net Income
2.1B
↓ 93.25%
Net Profit Margin
3.62%
↓ 27.65%
Q3 FY22Q/Q Change
Revenue
22.6B
↓ 18.4%
Net Income
8.6B
↓ 13.1%
Net Profit Margin
38.02%
↑ 2.31%
Q4 FY22Q/Q Change
Revenue
24.3B
↑ 7.3%
Net Income
5.0B
↓ 41.98%
Net Profit Margin
20.56%
↓ 17.46%
Q1 FY23Q/Q Change
Revenue
18.3B
↓ 24.73%
Net Income
5.5B
↑ 10.99%
Net Profit Margin
30.32%
↑ 9.76%
Q2 FY23Q/Q Change
Revenue
12.7B
↓ 30.35%
Net Income
2.3B
↓ 58.02%
Net Profit Margin
18.27%
↓ 12.05%
Q3 FY23Q/Q Change
Revenue
13.2B
↑ 3.91%
Net Income
-2.4B
↓ 202.88%
Net Profit Margin
-18.09%
↓ 36.36%
Q4 FY23Q/Q Change
Revenue
14.2B
↑ 7.69%
Net Income
-3.3B
↑ 39.68%
Net Profit Margin
-23.47%
↓ 5.38%
FY18Y/Y Change
Total Assets
159.4B
↓ 7.2%
Total Liabilities
95.7B
↓ 4.47%
FY19Y/Y Change
Total Assets
167.5B
↑ 5.06%
Total Liabilities
104.0B
↑ 8.76%
FY20Y/Y Change
Total Assets
154.2B
↓ 7.92%
Total Liabilities
90.8B
↓ 12.77%
FY21Y/Y Change
Total Assets
181.5B
↑ 17.67%
Total Liabilities
104.0B
↑ 14.61%
FY22Y/Y Change
Total Assets
197.2B
↑ 8.67%
Total Liabilities
101.3B
↓ 2.62%
FY23Y/Y Change
Total Assets
226.5B
↑ 14.86%
Total Liabilities
137.2B
↑ 35.47%
Q3 FY22Q/Q Change
Total Assets
195.3B
↑ 0.03%
Total Liabilities
102.5B
↓ 4.97%
Q4 FY22Q/Q Change
Total Assets
197.2B
↑ 0.95%
Total Liabilities
101.3B
↓ 1.14%
Q1 FY23Q/Q Change
Total Assets
195.6B
↓ 0.81%
Total Liabilities
94.4B
↓ 6.82%
Q2 FY23Q/Q Change
Total Assets
220.2B
↑ 12.55%
Total Liabilities
120.9B
↑ 28.07%
Q3 FY23Q/Q Change
Total Assets
215.0B
↓ 2.34%
Total Liabilities
117.8B
↓ 2.53%
Q4 FY23Q/Q Change
Total Assets
226.5B
↑ 5.34%
Total Liabilities
137.2B
↑ 16.46%
FY18Y/Y Change
Operating Cash Flow
15.8B
↓ 3.9%
Investing Cash Flow
4.5B
↓ 195.44%
Financing Cash Flow
-20.4B
↑ 56.82%
FY19Y/Y Change
Operating Cash Flow
12.6B
↓ 20.47%
Investing Cash Flow
-3.9B
↓ 187.18%
Financing Cash Flow
-8.5B
↓ 58.49%
FY20Y/Y Change
Operating Cash Flow
14.4B
↑ 14.42%
Investing Cash Flow
-4.3B
↑ 8.26%
Financing Cash Flow
-9.6B
↑ 13.72%
FY21Y/Y Change
Operating Cash Flow
32.6B
↑ 126.2%
Investing Cash Flow
-22.5B
↑ 427.89%
Financing Cash Flow
-9.8B
↑ 1.73%
FY22Y/Y Change
Operating Cash Flow
29.3B
↓ 10.17%
Investing Cash Flow
-15.8B
↓ 30.0%
Financing Cash Flow
-14.8B
↑ 51.12%
FY23Y/Y Change
Operating Cash Flow
8.7B
↓ 70.27%
Investing Cash Flow
-32.3B
↑ 104.51%
Financing Cash Flow
26.1B
↓ 275.72%
Q3 FY22Q/Q Change
Operating Cash Flow
6.0B
↓ 26.88%
Investing Cash Flow
-627.0M
↓ 94.46%
Financing Cash Flow
-5.8B
↓ 328.61%
Q4 FY22Q/Q Change
Operating Cash Flow
8.6B
↑ 43.66%
Investing Cash Flow
-15.8B
↑ 2417.22%
Financing Cash Flow
-5.0B
↓ 12.95%
Q1 FY23Q/Q Change
Operating Cash Flow
1.2B
↓ 85.88%
Investing Cash Flow
3.3B
↓ 121.0%
Financing Cash Flow
-2.8B
↓ 44.75%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.2B
↓ 199.67%
Investing Cash Flow
-25.5B
↓ 868.78%
Financing Cash Flow
27.2B
↓ 1080.66%
Q3 FY23Q/Q Change
Operating Cash Flow
3.5B
↓ 386.09%
Investing Cash Flow
888.0M
↓ 103.48%
Financing Cash Flow
-3.8B
↓ 113.91%
Q4 FY23Q/Q Change
Operating Cash Flow
5.2B
↑ 51.62%
Investing Cash Flow
-11.0B
↓ 1338.29%
Financing Cash Flow
5.4B
↓ 244.01%

Technicals Summary

Sell

Neutral

Buy

Pfizer Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pfizer Inc.
Pfizer Inc.
-8.45%
-18.93%
-34.61%
-34.69%
-36.8%
Procter & Gamble Company, The
Procter & Gamble Company, The
1.25%
8.51%
5.16%
23.84%
53.55%
Johnson & Johnson
Johnson & Johnson
-5.75%
-1.46%
-9.72%
-10.54%
4.58%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pfizer Inc.
Pfizer Inc.
71.0
71.0
0.26
2.21
0.02
0.02
0.06
15.77
Procter & Gamble Company, The
Procter & Gamble Company, The
26.61
26.61
3.28
6.53
0.32
0.11
0.02
20.87
Johnson & Johnson
Johnson & Johnson
19.99
19.99
0.89
10.66
0.18
0.08
0.03
28.57
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pfizer Inc.
Pfizer Inc.
Buy
$148.8B
-36.8%
71.0
3.62%
Procter & Gamble Company, The
Procter & Gamble Company, The
Buy
$383.8B
53.55%
26.61
17.99%
Johnson & Johnson
Johnson & Johnson
Hold
$357.9B
4.58%
19.99
47.37%

Institutional Holdings

  • Vanguard Group Inc

    8.95%

  • BlackRock Inc

    7.64%

  • State Street Corporation

    5.08%

  • Wellington Management Company LLP

    4.22%

  • Capital World Investors

    3.06%

  • Geode Capital Management, LLC

    1.93%

Corporate Announcements

  • Pfizer Inc. Dividends March,2024

    In the quarter ending March,2024. Pfizer Inc. has declared dividend of $0.42

    Read More

Company Information

“Pfizer Inc., founded in 1849 by Charles Pfizer and Charles F. Erhart, is an American Biotechnology and Pharmaceutical giant. It is currently headquartered in New York City, United States with worldwide operations and distributions. To ensure that the medicinal and vaccine requirements of every patient and individual are met, Pfizer has been adopting a rigorous and scientific approach towards its supply chain. They now have a network of 58 manufacturing sites around the world under Pfizer Global Supply (PGS). To further expand its operations in the research and pharmaceutical sphere, it entered various merger and acquisitions deals with other players including Wyeth, Pharmacia, Warner-Lambert, Innopharma, etc. Its primary focus areas include internal medicine, rare diseases, vaccines, inflammation, immunology, oncology, and anti-infectives. They have major R&D platforms in the fields of gene therapy, precision medicine, biosimilars, medicinal sciences, and maternal immunizations. Pfizer Is traded under the ticker symbol of PFE. The financials of Pfizer are as follows: While Pfizer clocked a revenue of $41.908 billion for 2020, its net income amounted to $6985 million for the same period. Pfizer has made significant contributions in the fight against Covid-19 and has been successful in the early development of the Pfizer-BioNTech Vocid-19 vaccine. In 2020, Pfizer achieved the Top Employer Certification for the 5th year in the UK. Going by the revenue, Pfizer is the 4th largest pharmaceutical company globally and the 3rd largest in terms of market capitalization. It is currently traded in NYSE and other indices, including S&P 100, S&P 500, and Russell 1000 Index. Currently Pfizer Inc. has a market cap of $148.75 Billion. It has a P.E ratio of 70.23. The shares of Pfizer Inc. are trading at $25.26. ” .

Organization
Pfizer Inc.
Employees
88000
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Industry
Health Technology

Discover More

FAQs